Header Logo

Connection

Ian Dunn to Mutation

Back to Details
This is a "connection" page, showing publications Ian Dunn has written about Mutation.
Ian Dunn
Connection Strength
3.459
Mutation
  1. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis. Cancer Med. 2021 07; 10(13):4415-4423.
    View in: PubMed
    Score: 0.559
  2. Genomic and Epigenomic Landscape in Meningioma. Neurosurg Clin N Am. 2016 Apr; 27(2):167-79.
    View in: PubMed
    Score: 0.391
  3. Spontaneous mutation in 2310061I04Rik results in reduced expression of mitochondrial genes and impaired brain myelination. PLoS One. 2024; 19(12):e0290487.
    View in: PubMed
    Score: 0.178
  4. Chordoma: Genetics and Contemporary Management. Int J Mol Sci. 2024 May 28; 25(11).
    View in: PubMed
    Score: 0.172
  5. Primary versus secondary gliosarcoma: a systematic review and meta-analysis. J Neurooncol. 2022 Aug; 159(1):195-200.
    View in: PubMed
    Score: 0.151
  6. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. J Neurooncol. 2022 Jul; 158(3):405-412.
    View in: PubMed
    Score: 0.150
  7. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021 Dec; 155(3):225-234.
    View in: PubMed
    Score: 0.144
  8. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer. 2020 Sep 21; 20(1):897.
    View in: PubMed
    Score: 0.133
  9. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018 04; 44(4):E3.
    View in: PubMed
    Score: 0.112
  10. High-grade meningiomas: biology and implications. Neurosurg Focus. 2018 04; 44(4):E2.
    View in: PubMed
    Score: 0.112
  11. Genomic Alterations in Sporadic Pituitary Tumors. Curr Neurol Neurosci Rep. 2018 02 02; 18(1):4.
    View in: PubMed
    Score: 0.111
  12. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291.
    View in: PubMed
    Score: 0.107
  13. Genomic profile of human meningioma cell lines. PLoS One. 2017; 12(5):e0178322.
    View in: PubMed
    Score: 0.106
  14. The genomic landscape of schwannoma. Nat Genet. 2016 11; 48(11):1339-1348.
    View in: PubMed
    Score: 0.101
  15. Landscape of Genomic Alterations in Pituitary Adenomas. Clin Cancer Res. 2017 Apr 01; 23(7):1841-1851.
    View in: PubMed
    Score: 0.101
  16. High incidence of TERT mutation in brain tumor cell lines. Brain Tumor Pathol. 2016 Jul; 33(3):222-7.
    View in: PubMed
    Score: 0.097
  17. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016 09; 125(3):525-35.
    View in: PubMed
    Score: 0.096
  18. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.095
  19. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.091
  20. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
    View in: PubMed
    Score: 0.088
  21. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
    View in: PubMed
    Score: 0.061
  22. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. J Clin Oncol. 2023 01 20; 41(3):618-628.
    View in: PubMed
    Score: 0.039
  23. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep. 2021 09 09; 11(1):18009.
    View in: PubMed
    Score: 0.036
  24. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
    View in: PubMed
    Score: 0.026
  25. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
    View in: PubMed
    Score: 0.025
  26. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
    View in: PubMed
    Score: 0.024
  27. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.024
  28. ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet. 2015 Jun; 208(6):345-50.
    View in: PubMed
    Score: 0.023
  29. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606.
    View in: PubMed
    Score: 0.022
  30. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
    View in: PubMed
    Score: 0.020
  31. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
    View in: PubMed
    Score: 0.020
  32. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29; 137(5):821-34.
    View in: PubMed
    Score: 0.015
  33. Integrative genomic approaches to understanding cancer. Biochim Biophys Acta. 2009 Jun; 1790(6):478-84.
    View in: PubMed
    Score: 0.015
  34. Genomics of human glioblastoma multiforme: a glimpse of the future. Neurosurgery. 2008 Dec; 63(6):15.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.